[An experimental and clinical study of the effect of ketotifen in the treatment of extrinsic bronchial asthma (author's transl)].
The therapeutic value of ketotifen (Zaditen), a new anti-allergic drug, was studied in patients with extrinsic bronchial asthma. a) In 8 persons the protective effect on bronchial provocation tests with allergen was examined 3 and 14 days after treatment and compared with cromoglycate (Intal); b) 19 patients were treated for 6 months with 2 x 1 milligram ketotifen (n = 7), 2 x 2 mg ketotifen (n = 7), 2 x 1 mg clemastine (Tavegil) (n = 5). The results were as follows: a) The amount of inhaled allergen causing a fall of 20% in FEV1.0/VC was 9-12 times larger with both therapeutic regimens. b) Ketotifen definitely improved the asthmatic symptoms as compared with clemastine. The improvement was independent of the dosage. Side-effects occurred more frequently with clemastine. The study confirms the in vitro demonstrated anti-analphylactic properties of ketotifen; that it can be taken by mouth is of particular clinical interest.
D001249:Asthma / Q000188:drug therapy*; D002974:Clemastine / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004205:Cromolyn Sodium / Q000627:therapeutic use; D004341:Drug Evaluation; D006634:Histamine H1 Antagonists / Q000627:therapeutic use*; D006801:Humans; D010880:Piperidines / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*
D006634:Histamine H1 Antagonists; D010880:Piperidines; D013876:Thiophenes; D002974:Clemastine; D004205:Cromolyn Sodium
Experimentelle und klinische Erfahrungen in der Behandlung des exogenen allergischen Asthma bronchiale mit Ketotifen (Zaditen).